Opaleye Management Inc. - 28 Jan 2022 Form 4 Insider Report for Tracon Pharmaceuticals, Inc.

Role: 10%+ Owner
Signature: Opaleye Management Inc., By: /s/ James Silverman, President
Issuer symbol: N/A
Transactions as of: 28 Jan 2022
Net transactions value: +$1,100
Form type: 4
Filing time: 31 Jan 2022, 15:05:32 UTC
Previous filing: 24 Jan 2022
Next filing: 17 Mar 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TCON	Common Stock, par value $0.001 per share	Purchase	$1,100	+500	+0.02%	$2.20^*	2,820,500	28 Jan 2022	By Opaleye, L.P.	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	TCON	Prefunded Warrants						1,889,513	28 Jan 2022	Common Stock	1,889,513	$0.0100	By Opaleye,L.P.	F3
holding	TCON	Prefunded Warrants						1,358,593	28 Jan 2022	Common Stock	1,358,593	$0.0100	By Opaleye,L.P.	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund.
F2	The common stock was purchased by the reporting person in open market transactions on the transaction date, with a purchase price of $2.20
F3	The warrants may not be exercised to the extent that such exercise would cause the reporting person and its affiliates to beneficially own more than 9.99% of the issuers then outstanding shares.